Home / Resource Library / Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, openlabel, multicenter, single-arm studyOrelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, openlabel, multicenter, single-arm study